A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

References

• NIH, Surveillance, Epidemiology, and End Results Program [Internet]. Cancer Stat Facts: Myeloma, 2010-2016. Available at: https://seer.cancer.gov/statfacts/html/mulmy.html.
   Google Scholar
• Nandakumar B, Binder M, Dispenzieri A, et al. Continued improvement in survival in multiple myeloma (MM) including high-risk patients. Presented at: American Society of Clinical Oncology Annual Meeting; May 31–June 4 2019. Chicago, Illinois. Suppl Abstract 8039
   Google Scholar
• Paquin AR, Kumar SK, Buadi FK, et al. Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. Blood Cancer J. 2018;8(12):125.
   PubMedGoogle Scholar
• Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004; 4(7):505–518.
   PubMed Web of Science ®Google Scholar
• Wang Y, Sun Y. Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis. Curr Cancer Drug Targets. 2002; 2(3):191–207.
   PubMed Web of Science ®Google Scholar
• Bataille R, Robillard N, Avet-Loiseau H, et al. CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. Haematologica. 2005;90(5):706–707.
   PubMed Web of Science ®Google Scholar
• Sprynski AC, Hose D, Caillot L, et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood. 2009;113(19):4614–4626.
   PubMed Web of Science ®Google Scholar
• Chng WJ, Gualberto A, Fonseca R. IGF-1R is overexpressed in poor-prognostic subtypes of multiple myeloma. Leukemia. 2006;20(1):174–176.
   PubMed Web of Science ®Google Scholar
• Shelton JG, Steelman LS, White ER, et al. Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells. Cell Cycle (Georgetown, Tex.). 2004;3(3):370–379.
   Web of Science ®Google Scholar
• Menke DM, Horny HP, Griesser H, et al. Immunophenotypic and genotypic characterisation of multiple myelomas with adverse prognosis characterised by immunohistological expression of the T cell related antigen CD45RO (UCHL-1). J Clin Pathol. 1998;51(6):432–437.
   PubMed Web of Science ®Google Scholar
• Lin P, Owens R, Tricot G, et al. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121(4):482–488.
   PubMed Web of Science ®Google Scholar
• Kumar S, Rajkumar SV, Kimlinger T, et al. CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations. Leukemia. 2005;19(8):1466–1470.
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 2004;5(3):221–230.
   PubMed Web of Science ®Google Scholar
• Liang SB, Yang XZ, Trieu Y, et al. Molecular target characterization and antimyeloma activity of the novel, insulin-like growth factor 1 receptor inhibitor, GTx-134. Clin Cancer Res. 2011;17(14):4693–4704.
   PubMed Web of Science ®Google Scholar
• Stromberg T, Ekman S, Girnita L, et al. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood. 2006;107(2):669–678.
   PubMed Web of Science ®Google Scholar
• Menu E, Jernberg-Wiklund H, De Raeve H, et al. Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival. Int J Cancer. 2007;121(8):1857–1861.
   PubMed Web of Science ®Google Scholar
• Menu E, Jernberg-Wiklund H, Stromberg T, et al. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood. 2006;107(2):655–660.
   PubMed Web of Science ®Google Scholar
• Maiso P, Ocio EM, Garayoa M, et al. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. Br J Haematol. 2008;141(4):470–482.
   PubMed Web of Science ®Google Scholar
• Baumann P, Hagemeier H, Mandl-Weber S, et al. Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001. Anticancer Drugs. 2009;20(4):259–266.
   PubMed Web of Science ®Google Scholar
• Descamps G, Gomez-Bougie P, Venot C, et al. A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45. Br J Cancer. 2009;100(2):366–369.
   PubMed Web of Science ®Google Scholar
• Kuhn DJ, Berkova Z, Jones RJ, et al. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood. 2012;120(16):3260–3270.
   PubMed Web of Science ®Google Scholar
• Ciuleanu T, Ahmed S, Kim J, et al. Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer. Br J Cancer. 2017;117(6):757–766.
   PubMed Web of Science ®Google Scholar
• Fassnacht M, Berruti A, Baudin E, et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015;16(4):426–435.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Harousseau JL, Durie B, et al.; International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691–4695.
   PubMed Web of Science ®Google Scholar
• Ji Q-S, Mulvihill MJ, Rosenfeld-Franklin M, et al. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. Mol Cancer Ther. 2007;6(8):2158–2167.
   PubMed Web of Science ®Google Scholar
• del Rincon JP, Iida K, Gaylinn BD, et al. Growth hormone regulation of p85alpha expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance. Diabetes. 2007;56(6):1638–1646.
   PubMed Web of Science ®Google Scholar
• Goldman JW, Mendenhall MA, Rettinger SR. Hyperglycemia associated with targeted oncologic treatment: mechanisms and management. Oncologist. 2016;21(11):1326–1336.
   PubMed Web of Science ®Google Scholar
• Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem. 2009;1(6):1153–1171.
   PubMed Web of Science ®Google Scholar
• Descamps G, Wuillème-Toumi S, Trichet V, et al. CD45neg but not CD45pos human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a Murine anti-IGF-1R monoclonal antibody, mAVE1642. J Immunol. 2006;177(6):4218–4223.
   PubMed Web of Science ®Google Scholar
• Puzanov I, Lindsay CR, Goff L, et al. A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. Clin Cancer Res. 2015;21(4):701–711.
   PubMed Web of Science ®Google Scholar
• Chen S, Hu M, Shen M, et al. IGF-1 facilitates thrombopoiesis primarily through Akt activation. Blood. 2018;132(2):210–222.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–766.
   PubMed Web of Science ®Google Scholar
• San-Miguel JF, Hungria VTM, Yoon S-S, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195–1206.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Oriol A, Beksac M, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(6):781–794.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(10):1327–1337.
   PubMed Web of Science ®Google Scholar